Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis

Aki, S; Eskiyurt, N; Akarirmak, U; Tuzun, F; Eryavuz, M; Alper, S; Arpacioglu, O; Atalay, F; Kavuncu, VURAL; Kokino, S; Kuru, O; Nas, K; Ozerbil, O; Savas, G; Sendur, OF; Soy, D; Akyuz, G

doi:10.3349/ymj.2003.44.6.961

Gastrointestinal side effect profile due to the use of alendronate in the treatment of osteoporosis

Aki S., Eskiyurt N., Akarirmak U., Tuzun F., Eryavuz M., Alper S., ...Daha Fazla

YONSEI MEDICAL JOURNAL, cilt.44, sa.6, ss.961-967, 2003 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 44 Sayı: 6
Basım Tarihi: 2003
Doi Numarası: 10.3349/ymj.2003.44.6.961
Dergi Adı: YONSEI MEDICAL JOURNAL
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.961-967
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Kütahya Sağlık Bilimleri Üniversitesi Adresli: Hayır

Özet

The aim of our study was to evaluate the upper gastrointestinal (GI) tract side effect profile in 759 female patients that had taken alendronate (10 mg/day), for at least 6 months, for the treatment of osteoporosis, in relation to the safety of alendronate and the compliance of patients to its absorption rules.